Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam (Q38075482)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 January 2013

Language	Label	Description	Also known as
English	Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam	scientific article published on 18 January 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1 reference

Europe PubMed Central

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Pseudomonas aeruginosa

0 references

1 reference

based on heuristic

inferred from title

Enterobacteriaceae

1 reference

based on heuristic

inferred from title

Sujata M Bhavnani

3

object named as

Sujata M Bhavnani

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

6

object named as

Ronald N Jones

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Michael N Dudley

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Paul G Ambrose

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

William A Craig

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Mary Jane Ferraro

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute

7

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

0 references

publication date

18 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1301-1309

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Is cefepime safe for clinical use? A Bayesian viewpoint

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT017

21 January 2018

Identifiers

10.1093/CID/CIT017

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

release_72msisxigvfelae4gibg4rafwm

1 reference

https://api.fatcat.wiki/v0/release/72msisxigvfelae4gibg4rafwm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38075482&oldid=2155753398"